Purple Biotech Ltd.
Simbols: PPBT
NASDAQ
0.67
USDTirgus cena šodien
-0.6807
P/E koeficients
-0.0254
PEG koeficients
17.38M
MRK Cap
- 0.00%
DIV ienesīgums
Purple Biotech Ltd. (PPBT) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 73.01 | 15.4 | 32.1 | 47.2 | |||||||||||
balance-sheet.row.short-term-investments | 4.34 | 0.9 | 17.1 | 36.3 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 3.29 | 0.4 | 1.1 | 1.3 | |||||||||||
balance-sheet.row.total-current-assets | 76.3 | 15.8 | 33.3 | 48.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 2.18 | 0.5 | 0.7 | 0.9 | |||||||||||
balance-sheet.row.goodwill | 112.06 | 28 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0.11 | 0 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 112.18 | 28 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.total-non-current-assets | 114.36 | 28.5 | 21.4 | 21.7 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.account-payables | 10.15 | 3.5 | 2.1 | 1.5 | |||||||||||
balance-sheet.row.short-term-debt | 0.74 | 0.2 | 0.2 | 0.2 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0.87 | 0.2 | 0.3 | 0.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 13.01 | 3.5 | 4.7 | 2.6 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 3.95 | 2.8 | 0.5 | 0.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 1.42 | 0.2 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.total-liab | 27.85 | 10 | 7.5 | 5.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -520.12 | -137.5 | -117.6 | -95.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 69.19 | 38.5 | 10.1 | 8.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 613.23 | 133.2 | 154.4 | 152 | |||||||||||
balance-sheet.row.total-stockholders-equity | 162.29 | 34.2 | 46.9 | 64.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.minority-interest | 0.51 | 0.1 | 0.2 | 0.3 | |||||||||||
balance-sheet.row.total-equity | 162.81 | 34.3 | 47.1 | 65.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 190.66 | - | - | - | |||||||||||
Total Investments | 4.34 | 0.9 | 17.1 | 36.5 | |||||||||||
balance-sheet.row.total-debt | 1.61 | 0.4 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.net-debt | -67.07 | -14.1 | -14.5 | -10.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -19.95 | -19.9 | -21.8 | -17.8 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
cash-flows.row.deferred-income-tax | 0.64 | -0.8 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 1.88 | 1.9 | 2.4 | 2.1 | |||||||||||
cash-flows.row.change-in-working-capital | 0.27 | 0.3 | 3.3 | 0.6 | |||||||||||
cash-flows.row.account-receivables | 0 | 0.2 | 0.3 | -0.3 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0.6 | |||||||||||
cash-flows.row.account-payables | 1.33 | 1.3 | 0.8 | 0.3 | |||||||||||
cash-flows.row.other-working-capital | -1.06 | -1.2 | 2.1 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | -2.9 | -0.9 | -0.8 | -0.1 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -19.86 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.acquisitions-net | -3.55 | -3.5 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 16.68 | 16.7 | 19.8 | 13.2 | |||||||||||
cash-flows.row.other-investing-activites | 0.67 | 0 | 0.3 | 0.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 13.8 | 13.1 | 19.9 | 13.4 | |||||||||||
cash-flows.row.debt-repayment | -0.17 | -0.2 | -0.2 | -0.2 | |||||||||||
cash-flows.row.common-stock-issued | 5.86 | 5.7 | 1.5 | 0.6 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | -0.93 | -0.9 | -0.2 | 1.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.46 | 5.5 | 1.1 | 1.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0.1 | -0.2 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -0.54 | -0.5 | 4.1 | -0.4 | |||||||||||
cash-flows.row.cash-at-end-of-period | 68.68 | 14.5 | 15 | 10.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 69.22 | 15 | 10.9 | 11.2 | |||||||||||
cash-flows.row.operating-cash-flow | -19.86 | -19.2 | -16.7 | -15.1 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.free-cash-flow | -19.86 | -19.2 | -17 | -15.2 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | -0.9 | -0.3 | |||||||||||
income-statement-row.row.cost-of-revenue | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
income-statement-row.row.gross-profit | -0.2 | -0.2 | -1.1 | -0.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 17.03 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 22.22 | 22.1 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.cost-and-expenses | 22.27 | 22.3 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.interest-income | 0.47 | 0.5 | 1 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.47 | 0.2 | 1.2 | 0.6 | |||||||||||
income-statement-row.row.ebitda-caps | -20.96 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -12 | -22.3 | -22.6 | -17.9 | |||||||||||
income-statement-row.row.income-before-tax | -19.98 | -20 | -21.8 | -17.8 | |||||||||||
income-statement-row.row.income-tax-expense | -9.54 | -0.1 | -0.9 | 0.6 | |||||||||||
income-statement-row.row.net-income | -19.88 | -19.9 | -20.8 | -18.5 |
Biežāk uzdotie jautājumi
Kas ir Purple Biotech Ltd. (PPBT) kopējie aktīvi?
Purple Biotech Ltd. (PPBT) kopējie aktīvi ir 44302000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.807.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir Purple Biotech Ltd. (PPBT) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -19880000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 351000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 22072000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 14489000.000.